R Kiplin Guy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7007362/publications.pdf

Version: 2024-02-01

195 papers	13,056 citations	24978 57 h-index	27345 106 g-index
220 all docs	220 docs citations	220 times ranked	16019 citing authors

#	Article	IF	Citations
1	Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice. Malaria Journal, 2022, 21, 49.	0.8	2
2	Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development. EBioMedicine, 2022, 80, 104065.	2.7	4
3	Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones. Malaria Journal, 2021, 20, 107.	0.8	7
4	Identification of Plasmodium falciparum heat shock 90 inhibitors via molecular docking. Bioorganic and Medicinal Chemistry Letters, 2021, 35, 127818.	1.0	3
5	Improvement of Oral Bioavailability of Pyrazolo-Pyridone Inhibitors of the Interaction of DCN1/2 and UBE2M. Journal of Medicinal Chemistry, 2021, 64, 5850-5862.	2.9	8
6	Amino-Substituted 3-Aryl- and 3-Heteroarylquinolines as Potential Antileishmanial Agents. Journal of Medicinal Chemistry, 2021, 64, 12152-12162.	2.9	5
7	Antimalarial activity of 2,6-dibenzylidenecyclohexanone derivatives. Bioorganic and Medicinal Chemistry Letters, 2021, 47, 128216.	1.0	1
8	Antimalarial activity of tetrahydro-Î²-carbolines targeting the ATP binding pocket of the Plasmodium falciparum heat shock 90 protein. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127502.	1.0	10
9	Evaluation of 1,1-cyclopropylidene as a thioether isostere in the 4-thio-thienopyrimidine (TTP) series of antimalarials. Bioorganic and Medicinal Chemistry, 2020, 28, 115758.	1.4	5
10	Synthesis and Structureâ€“Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4-b]pyridines. Journal of Medicinal Chemistry, 2020, 63, 11902-11919.	2.9	20
11	Universityâ€“pharmacy partnerships for COVID-19. Science, 2020, 369, 1441-1441.	6.0	0
12	Rapid repurposing of drugs for COVID-19. Science, 2020, 368, 829-830.	6.0	253
13	Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer. Cancer Research, 2020, 80, 3507-3518.	0.4	28
14	Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. Lancet Infectious Diseases, The, 2020, 20, 964-975.	4.6	47
15	Discovery of Novel Pyrazolo-pyridone DCN1 Inhibitors Controlling Cullin Neddylation. Journal of Medicinal Chemistry, 2019, 62, 8429-8442.	2.9	24
16	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nature Communications, 2019, 10, 2189.	5.8	26
17	Phenotypic Screens Reveal Posaconazole as a Rapidly Acting Amebicidal Combination Partner for Treatment of Primary Amoebic Meningoencephalitis. Journal of Infectious Diseases, 2019, 219, 1095-1103.	1.9	34
18	Report of the 2018-2019 Research and Graduate Affairs Committee. American Journal of Pharmaceutical Education, 2019, 83, 7595.	0.7	2

#	Article	IF	Citations
19	Cysteine modifiers suggest an allosteric inhibitory site on the CAL PDZ domain. Bioscience Reports, 2018, 38, .	1.1	9
20	Oxazole and thiazole analogs of sulindac for cancer prevention. Future Medicinal Chemistry, 2018, 10, 743-753.	1.1	8
21	Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. Journal of Medicinal Chemistry, 2018, 61, 2680-2693.	2.9	34
22	Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. Journal of Medicinal Chemistry, 2018, 61, 2694-2706.	2.9	41
23	CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss. Journal of Experimental Medicine, 2018, 215, 1187-1203.	4.2	75
24	Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 25-36.	1.4	23
25	A small diversity library of Î±-methyl amide analogs of sulindac for probing anticancer structure-activity relationships. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2136-2142.	1.0	6
26	Identification of Toll-like receptor signaling inhibitors based on selective activation of hierarchically acting signaling proteins. Science Signaling, 2018, 11, .	1.6	17
27	Shared Consensus Machine Learning Models for Predicting Blood Stage Malaria Inhibition. Journal of Chemical Information and Modeling, 2017, 57, 445-453.	2.5	15
28	Performance of a docking/molecular dynamics protocol for virtual screening of nutlin-class inhibitors of Mdmx. Journal of Molecular Graphics and Modelling, 2017, 74, 54-60.	1.3	12
29	Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia. ACS Omega, 2017, 2, 1985-2009.	1.6	9
30	Seeking the Elusive Long-Acting Ozonide: Discovery of Artefenomel (OZ439). Journal of Medicinal Chemistry, 2017, 60, 2651-2653.	2.9	17
31	Diverse amide analogs of sulindac for cancer treatment and prevention. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4614-4621.	1.0	21
32	Ventromorphins: A New Class of Small Molecule Activators of the Canonical BMP Signaling Pathway. ACS Chemical Biology, 2017, 12, 2436-2447.	1.6	20
33	Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. Cancer Research, 2017, 77, 4626-4638.	0.4	42
34	Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening. PLoS Neglected Tropical Diseases, 2017, 11, e0006157.	1.3	23
35	Blocking an N-terminal acetylationâ€“dependent protein interaction inhibits an E3 ligase. Nature Chemical Biology, 2017, 13, 850-857.	3.9	80
36	Screening and Development of New Inhibitors of FtsZ from M. Tuberculosis. PLoS ONE, 2016, 11, e0164100.	1.1	22

#	Article	IF	Citations
37	Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. PLoS Pathogens, 2016, 12, e1005763.	2.1	244
38	Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2016, 77, 1231-1243.	1.1	41
39	Flexibility is important for inhibition of the MDM2/p53 proteinâ€“protein interaction by cyclic Î²-hairpins. Organic and Biomolecular Chemistry, 2016, 14, 10386-10393.	1.5	22
40	Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides. Journal of Medicinal Chemistry, 2016, 59, 7950-7962.	2.9	40
41	Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles. ACS Central Science, 2016, 2, 687-701.	5.3	68
42	Diversity-oriented natural product platform identifies plant constituents targeting Plasmodium falciparum. Malaria Journal, 2016, 15, 270.	0.8	4
43	Monitoring Ligand-Induced Protein Ordering in Drug Discovery. Journal of Molecular Biology, 2016, 428, 1290-1303.	2.0	29
44	Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents. Journal of Medicinal Chemistry, 2016, 59, 559-577.	2.9	33
45	Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomes. Journal of Antimicrobial Chemotherapy, 2016, 71, 956-963.	1.3	5
46	Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma. Mini-Reviews in Medicinal Chemistry, 2016, 16, 430-454.	1.1	42
47	Current and emerging therapy for improving outcomes in patients with intraocular retinoblastoma. Expert Opinion on Orphan Drugs, 2015, 3, 1155-1166.	0.5	0
48	Identification of Selective Inhibitors of the Plasmodium falciparum Hexose Transporter PfHT by Screening Focused Libraries of Anti-Malarial Compounds. PLoS ONE, 2015, 10, e0123598.	1.1	23
49	Design, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 Interaction. PLoS ONE, 2015, 10, e0137867.	1.1	11
50	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT). Bioorganic and Medicinal Chemistry, 2015, 23, 5151-5155.	1.4	35
51	Potent Plasmodium falciparum Gametocytocidal Activity of Diaminonaphthoquinones, Lead Antimalarial Chemotypes Identified in an Antimalarial Compound Screen. Antimicrobial Agents and Chemotherapy, 2015, 59, 1389-1397.	1.4	16
52	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nature Genetics, 2015, 47, 607-614.	9.4	126
53	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 28, 343-356.	7.7	145
54	LC-MS- and ¹H NMR Spectroscopy-Guided Identification of Antifungal Diterpenoids from Sagittaria latifolia. Journal of Natural Products, 2015, 78, 2255-2259.	1.5	13

#	Article	IF	Citations
55	8-Triazolylpurines: Towards Fluorescent Inhibitors of the MDM2/p53 Interaction. PLoS ONE, 2015, 10, e0124423.	1.1	11
56	Antischistosomal versus Antiandrogenic Properties of Aryl Hydantoin Ro 13-3978. American Journal of Tropical Medicine and Hygiene, 2014, 90, 1156-1158.	0.6	8
57	(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5455-62.	3.3	199
58	A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia. Journal of Biomolecular Screening, 2014, 19, 158-167.	2.6	10
59	Dihydroquinazolinone Inhibitors of Proliferation of Blood and Liver Stage Malaria Parasites. Antimicrobial Agents and Chemotherapy, 2014, 58, 1516-1522.	1.4	12
60	Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma. Cancer Cell, 2014, 25, 516-529.	7.7	128
61	Development of a Cell-Based, High-Throughput Screening Assay for ATM Kinase Inhibitors. Journal of Biomolecular Screening, 2014, 19, 538-546.	2.6	32
62	UPLC-MS-ELSD-PDA as a Powerful Dereplication Tool to Facilitate Compound Identification from Small-Molecule Natural Product Libraries. Journal of Natural Products, 2014, 77, 902-909.	1.5	41
63	Antimalarials in Development in 2014. Chemical Reviews, 2014, 114, 11221-11241.	23.0	64
64	Organocatalytic, Diastereo- and Enantioselective Synthesis of Nonsymmetric cis-Stilbene Diamines: A Platform for the Preparation of Single-Enantiomer cis-Imidazolines for Proteinâ€“Protein Inhibition. Journal of Organic Chemistry, 2014, 79, 6913-6938.	1.7	41
65	Pharmacokinetics and Efficacy of the Spleen Tyrosine Kinase Inhibitor R406 after Ocular Delivery for Retinoblastoma. Pharmaceutical Research, 2014, 31, 3060-3072.	1.7	24
66	Repositioning: the fast track to new anti-malarial medicines?. Malaria Journal, 2014, 13, 143.	0.8	36
67	Treatment of Murine Cerebral Malaria by Artemisone in Combination with Conventional Antimalarial Drugs: Antiplasmodial Effects and Immune Responses. Antimicrobial Agents and Chemotherapy, 2014, 58, 4745-4754.	1.4	17
68	Targeted Inhibition of the MLL Transcriptional Complex By Proteosome Inhibitors Elicits a High Response Rate in Relapsed/Refractory MLL Rearranged Leukemia. Blood, 2014, 124, 972-972.	0.6	8
69	Optimization of Chloronitrobenzamides (CNBs) as Therapeutic Leads for Human African Trypanosomiasis (HAT). Journal of Medicinal Chemistry, 2013, 56, 2850-2860.	2.9	13
70	Optimization of the electrophile of chloronitrobenzamide leads active against Trypanosoma brucei. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4127-4131.	1.0	12
71	Antimalarial activity of 10-alkyl/aryl esters and -aminoethylethers of artemisinin. Bioorganic Chemistry, 2013, 46, 10-16.	2.0	14
72	Discovery of Novel Antimalarial Compounds Enabled by QSAR-Based Virtual Screening. Journal of Chemical Information and Modeling, 2013, 53, 475-492.	2.5	77

#	Article	IF	Citations
73	Quinolone-3-Diarylethers: A New Class of Antimalarial Drug. Science Translational Medicine, 2013, 5, 177ra37.	5.8	187
74	Synthesis and evaluation of methylsulfonylnitrobenzamides (MSNBAs) as inhibitors of the thyroid hormone receptorâ€“coactivator interaction. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1891-1895.	1.0	5
75	Anticancer Properties of Distinct Antimalarial Drug Classes. PLoS ONE, 2013, 8, e82962.	1.1	67
76	Synthesis of Artemiside and Its Effects in Combination with Conventional Drugs against Severe Murine Malaria. Antimicrobial Agents and Chemotherapy, 2012, 56, 163-173.	1.4	28
77	Discovery of the First Irreversible Small Molecule Inhibitors of the Interaction between the Vitamin D Receptor and Coactivators. Journal of Medicinal Chemistry, 2012, 55, 4640-4651.	2.9	43
78	Synthesis and Evaluation of Sulfonylnitrophenylthiazoles (SNPTs) as Thyroid Hormone Receptorâ€“Coactivator Interaction Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 2301-2310.	2.9	22
79	Lead Optimization of Antimalarial Propafenone Analogues. Journal of Medicinal Chemistry, 2012, 55, 6087-6093.	2.9	12
80	Lead Optimization of 3-Carboxyl-4(1H)-Quinolones to Deliver Orally Bioavailable Antimalarials. Journal of Medicinal Chemistry, 2012, 55, 4205-4219.	2.9	71
81	An All-Purpose Antimalarial Drug Target. Cell Host and Microbe, 2012, 11, 555-557.	5.1	9
82	On the Mechanism of Action of SJ-172550 in Inhibiting the Interaction of MDM4 and p53. PLoS ONE, 2012, 7, e37518.	1.1	49
83	Global Phenotypic Screening for Antimalarials. Chemistry and Biology, 2012, 19, 116-129.	6.2	120
84	Optimization of Propafenone Analogues as Antimalarial Leads. Journal of Medicinal Chemistry, 2011, 54, 7477-7485.	2.9	21
85	Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration. Drug Metabolism and Disposition, 2011, 39, 15-21.	1.7	53
86	Similarities and Differences between Two Modes of Antagonism of the Thyroid Hormone Receptor. ACS Chemical Biology, 2011, 6, 1096-1106.	1.6	13
87	Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening.. Journal of Medicinal Chemistry, 2011, 54, 8563-8573.	2.9	136
88	Synthesis and Evaluation of 7-Substituted 4-Aminoquinoline Analogues for Antimalarial Activity. Journal of Medicinal Chemistry, 2011, 54, 7084-7093.	2.9	38
89	MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochemical Pharmacology, 2011, 82, 24-34.	2.0	19
90	An Integrated InÂVitro and InÂVivo High-Throughput Screen Identifies Treatment Leads for Ependymoma. Cancer Cell, 2011, 20, 384-399.	7.7	105

#	Article	IF	Citations
91	Targeting the p53 Pathway in Retinoblastoma with Subconjunctival Nutlin-3a. Cancer Research, 2011, 71, 4205-4213.	0.4	89
92	A Quantitative High-Throughput Screen Identifies Novel Inhibitors of the Interaction of Thyroid Receptor Î² with a Peptide of Steroid Receptor Coactivator 2. Journal of Biomolecular Screening, 2011, 16, 618-627.	2.6	15
93	Methylsulfonylnitrobenzoates, a New Class of Irreversible Inhibitors of the Interaction of the Thyroid Hormone Receptor and Its Obligate Coactivators That Functionally Antagonizes Thyroid Hormone. Journal of Biological Chemistry, 2011, 286, 11895-11908.	1.6	30
94	Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11878-11883.	3.3	118
95	Ligand Competition Binding Assay for the Androgen Receptor. Methods in Molecular Biology, 2011, 776, 59-68.	0.4	4
96	An Automated Approach to Efficiently Reformat a Large Collection of Compounds. Current Chemical Genomics, 2011, 5, 42-47.	2.0	5
97	Synthesis and structureâ€“activity relationships of antimalarial 4-oxo-3-carboxyl quinolones. Bioorganic and Medicinal Chemistry, 2010, 18, 2756-2766.	1.4	38
98	Optimization of purine-nitrile TbcatB inhibitors for use in vivo and evaluation of efficacy in murine models. Bioorganic and Medicinal Chemistry, 2010, 18, 8302-8309.	1.4	9
99	Discovery of halo-nitrobenzamides with potential application against human African trypanosomiasis. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 149-152.	1.0	11
100	Podophyllotoxin analogues active versus Trypanosoma brucei. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1787-1791.	1.0	8
101	Chemical genetics of Plasmodium falciparum. Nature, 2010, 465, 311-315.	13.7	515
102	Discovery of Potent and Selective Inhibitors of Trypanosoma brucei Ornithine Decarboxylase. Journal of Biological Chemistry, 2010, 285, 16771-16781.	1.6	33
103	Optimization of a Non-Radioactive High-Throughput Assay for Decarboxylase Enzymes. Assay and Drug Development Technologies, 2010, 8, 175-185.	0.6	15
104	Evaluation of Diarylureas for Activity Against Plasmodium falciparum. ACS Medicinal Chemistry Letters, 2010, 1, 460-465.	1.3	41
105	Development of a New Generation of 4-Aminoquinoline Antimalarial Compounds Using Predictive Pharmacokinetic and Toxicology Models. Journal of Medicinal Chemistry, 2010, 53, 3685-3695.	2.9	50
106	Identification and Characterization of the First Small Molecule Inhibitor of MDMX. Journal of Biological Chemistry, 2010, 285, 10786-10796.	1.6	171
107	Automated High-Throughput System to Fractionate Plant Natural Products for Drug Discovery. Journal of Natural Products, 2010, 73, 751-754.	1.5	79
108	Chemical Approaches to Nuclear Receptors in MetabolismA report on the workshop â€œChemical Approaches to Nuclear Receptors and Metabolism,â€•sponsored by National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA, 16 to 17 April 2009.. Science Signaling, 2009, 2, mr5.	1.6	2

#	Article	IF	Citations
109	Non-competitive androgen receptor inhibition in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7233-7238.	3.3	96
110	Inhibition of a viral enzyme by a small-molecule dimer disruptor. Nature Chemical Biology, 2009, 5, 640-646.	3.9	77
111	A road less traveled by: Exploring a decade of Ellman chemistry. Bioorganic and Medicinal Chemistry, 2009, 17, 1088-1093.	1.4	4
112	Antimalarial activity of thiosemicarbazones and purine derived nitriles. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3546-3549.	1.0	33
113	Improvement of Pharmacological Properties of Irreversible Thyroid Receptor Coactivator Binding Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 3892-3901.	2.9	51
114	Novel Flufenamic Acid Analogues as Inhibitors of Androgen Receptor Mediated Transcription. ACS Chemical Biology, 2009, 4, 834-843.	1.6	21
115	Structure-Guided Development of Selective TbcatB Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 6489-6493.	2.9	25
116	Quantification of the Vitamin D Receptorâ^'Coregulator Interaction. Biochemistry, 2009, 48, 1454-1461.	1.2	62
117	A High-Throughput Ligand Competition Binding Assay for the Androgen Receptor and Other Nuclear Receptors. Journal of Biomolecular Screening, 2009, 14, 43-48.	2.6	21
118	Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2883-2885.	1.0	52
119	Synthesis and characterization of BODIPY-labeled colchicine. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5867-5870.	1.0	7
120	Development of Potent Purine-Derived Nitrile Inhibitors of the Trypanosomal Protease TbcatB. Journal of Medicinal Chemistry, 2008, 51, 545-552.	2.9	58
121	Partial Acetylation of Lysine Residues Improves Intraprotein Cross-Linking. Analytical Chemistry, 2008, 80, 951-960.	3.2	34
122	A surface on the androgen receptor that allosterically regulates coactivator binding. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16074-16079.	3.3	269
123	Structural Insight into the Mode of Action of a Direct Inhibitor of Coregulator Binding to the Thyroid Hormone Receptor. Molecular Endocrinology, 2007, 21, 2919-2928.	3.7	57
124	Assay Optimization and Screening of RNA-Protein Interactions by AlphaScreen. Journal of Biomolecular Screening, 2007, 12, 946-955.	2.6	38
125	An Antagonist of Dishevelled Protein-Protein Interaction Suppresses Î²-Cateninâ€"Dependent Tumor Cell Growth. Cancer Research, 2007, 67, 573-579.	0.4	223
126	Planarity and Constraint of the Carbonyl Groups in 1,2-Diones Are Determinants for Selective Inhibition of Human Carboxylesterase 1. Journal of Medicinal Chemistry, 2007, 50, 5727-5734.	2.9	37

#	Article	IF	Citations
127	Design of a selective chemical probe for class I PDZ domains. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 546-548.	1.0	13
128	The interdependence between screening methods and screening libraries. Current Opinion in Chemical Biology, 2007, 11, 244-251.	2.8	54
129	Interaction between the androgen receptor and a segment of its corepressor SHP. Acta Crystallographica Section D: Biological Crystallography, 2007, 63, 1198-1200.	2.5	20
130	Reporting data from high-throughput screening of small-molecule libraries. Nature Chemical Biology, 2007, 3, 438-441.	3.9	97
131	Scaffold composition and biological relevance of screening libraries. Nature Chemical Biology, 2007, 3, 442-446.	3.9	164
132	Activity of piperaquine and other 4-aminoquinoline antiplasmodial drugs against chloroquine-sensitive and resistant blood-stages of Plasmodium falciparum. Biochemical Pharmacology, 2007, 73, 1910-1926.	2.0	78
133	Inhibitors of the Interaction of a Thyroid Hormone Receptor and Coactivators:â€‰ Preliminary Structureâ"Activity Relationships. Journal of Medicinal Chemistry, 2007, 50, 5269-5280.	2.9	41
134	Rational design of a nonpeptide general chemical scaffold for reversible inhibition of PDZ domain interactions. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 549-552.	1.0	36
135	An Î±-Helical Peptidomimetic Inhibitor of the HIV-1 Revâ"RRE Interaction. Journal of the American Chemical Society, 2006, 128, 3496-3497.	6.6	51
136	Incorporation of an Intramolecular Hydrogen-Bonding Motif in the Side Chain of 4-Aminoquinolines Enhances Activity against Drug-Resistant P. falciparum. Journal of Medicinal Chemistry, 2006, 49, 4535-4543.	2.9	76
137	Discovery of Trypanocidal Compounds by Whole Cell HTS of Trypanosoma brucei. Chemical Biology and Drug Design, 2006, 67, 355-363.	1.5	97
138	Searching for New Antimalarial Therapeutics amongst Known Drugs. Chemical Biology and Drug Design, 2006, 67, 409-416.	1.5	110
139	Inactivation of the p53 pathway in retinoblastoma. Nature, 2006, 444, 61-66.	13.7	550
140	Structureâ€"activity relationship study of 9-aminoacridine compounds in scrapie-infected neuroblastoma cells. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4913-4916.	1.0	29
141	Synthesis of highly substituted dibenzo[b,f]azocines and their evaluation as protein kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5360-5363.	1.0	17
142	Synthesis and Testing of a Focused Phenothiazine Library for Binding to HIV-1 TAR RNA. Chemistry and Biology, 2006, 13, 993-1000.	6.2	68
143	Parallel synthesis of 9-aminoacridines and their evaluation against chloroquine-resistant Plasmodium falciparum. Bioorganic and Medicinal Chemistry, 2006, 14, 334-343.	1.4	74
144	Proteomimetic Libraries:Â Design, Synthesis, and Evaluation of p53â"MDM2 Interaction Inhibitors. ACS Combinatorial Science, 2006, 8, 315-325.	3.3	72

#	Article	IF	Citations
145	Parallel Synthesis of Diarylureas and Their Evaluation as Inhibitors of Insulin-Like Growth Factor Receptor. ACS Combinatorial Science, 2006, 8, 784-790.	3.3	15
146	A High-Throughput Screening Method to Identify Small Molecule Inhibitors of Thyroid Hormone Receptor Coactivator Binding. Science Signaling, 2006, 2006, pl3-pl3.	1.6	27
147	Modeling Small Moleculeâ€RNA Interactions: Applications to HIV TAR RNA. FASEB Journal, 2006, 20, A73.	0.2	0
148	Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 121-123.	1.0	143
149	Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1015-1018.	1.0	103
150	High-throughput assays for promiscuous inhibitors. , 2005, 1, 146-148.		300
151	Discovery of Potent Thiosemicarbazone Inhibitors (V) of Rhodesain and Cruzain.. ChemInform, 2005, 36, no.	0.1	0
152	Synthesis of Ring-Substituted 4-Aminoquinolines and Evaluation of Their Antimalarial Activities.. ChemInform, 2005, 36, no.	0.1	0
153	Discovery of Small Molecule Inhibitors of the Interaction of the Thyroid Hormone Receptor with Transcriptional Coregulators. Journal of Biological Chemistry, 2005, 280, 43048-43055.	1.6	96
154	Coregulator Interactions with the Thyroid Hormone Receptor. Molecular and Cellular Proteomics, 2005, 4, 475-482.	2.5	29
155	The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor. Journal of Biological Chemistry, 2005, 280, 8060-8068.	1.6	139
156	Structural Analyses Reveal Phosphatidyl Inositols as Ligands for the NR5 Orphan Receptors SF-1 and LRH-1. Cell, 2005, 120, 343-355.	13.5	359
157	A Solid-Phase Approach to the Phallotoxins:Â Total Synthesis of [Ala7]-Phalloidin. Journal of Organic Chemistry, 2005, 70, 4578-4584.	1.7	38
158	A Convenient Procedure for Parallel Ester Hydrolysis. Synlett, 2004, 2004, 2391-2393.	1.0	2
159	Quantitative Proteomics of the Thyroid Hormone Receptor-Coregulator Interactions. Journal of Biological Chemistry, 2004, 279, 27584-27590.	1.6	58
160	Gene expression as a drug discovery tool. Nature Genetics, 2004, 36, 214-215.	9.4	30
161	Synthesis of Medium Ring Heterocycles Using an Intramolecular Heck Reaction.. ChemInform, 2004, 35, no.	0.1	0
162	Ligand-Selective Inhibition of the Interaction of Steroid Receptor Coactivators and Estrogen Receptor Isoforms. Chemistry and Biology, 2004, 11, 273-281.	6.2	41

#	Article	IF	Citations
163	A novel protein crosslinking reagent for the determination of moderate resolution protein structures by mass spectrometry (MS3-D). Bioorganic and Medicinal Chemistry Letters, 2004, 14, 427-429.	1.0	33
164	Parallel Synthesis and Antimalarial Screening of a 4-Aminoquinoline Library. ACS Combinatorial Science, 2004, 6, 437-442.	3.3	57
165	Synthesis of Medium Ring Heterocycles Using an Intramolecular Heck Reaction. Organic Letters, 2004, 6, 3005-3007.	2.4	89
166	A Metallopeptide Assembly of the HIV-1 gp41 Coiled Coil Is an Ideal Receptor in Fluorescence Detection of Ligand Binding. Angewandte Chemie - International Edition, 2003, 42, 5325-5328.	7.2	33
167	Isotopically labeled crosslinking reagents: resolution of mass degeneracy in the identification of crosslinked peptides. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4023-4026.	1.0	48
168	Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorganic and Medicinal Chemistry, 2003, 11, 4113-4120.	1.4	62
169	Role of Electrostatic Interactions in PDZ Domain Ligand Recognitionâ€. Biochemistry, 2003, 42, 2797-2805.	1.2	50
170	Novel Selective Inhibitors of the Interaction of Individual Nuclear Hormone Receptors with a Mutually Shared Steroid Receptor Coactivator 2. Journal of the American Chemical Society, 2003, 125, 6852-6853.	6.6	92
171	A Selective Irreversible Inhibitor Targeting a PDZ Protein Interaction Domain. Journal of the American Chemical Society, 2003, 125, 12074-12075.	6.6	70
172	Nanomolar Affinity Small Molecule Correctors of Defective Î”F508-CFTR Chloride Channel Gating. Journal of Biological Chemistry, 2003, 278, 35079-35085.	1.6	192
173	Steroid Receptor Coactivator Peptidomimetics. Methods in Enzymology, 2003, 364, 223-246.	0.4	10
174	A Novel 2â€˜-(N-Methylpyridinium Acetate) Prodrug of Paclitaxel Induces Superior Antitumor Responses in Preclinical Cancer Models. Bioconjugate Chemistry, 2002, 13, 1093-1099.	1.8	38
175	Investigation of the PDZ domain ligand binding site using chemically modified peptides. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2471-2474.	1.0	13
176	An Inhibitor of the Interaction of Thyroid Hormone Receptor Î² and Glucocorticoid Interacting Protein 1. Journal of the American Chemical Society, 2001, 123, 1525-1526.	6.6	40
177	Inhibition of sonic hedgehog autoprocessing in cultured mammalian cells by sterol deprivation. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 7307-7312.	3.3	61
178	Copper-Mediated Cross-Coupling of Aryl Boronic Acids and Alkyl Thiols. Organic Letters, 2000, 2, 2019-2022.	2.4	303
179	MAGI-1, a Membrane-associated Guanylate Kinase with a Unique Arrangement of Protein-Protein Interaction Domains. Journal of Biological Chemistry, 1997, 272, 31589-31597.	1.6	186
180	The Chemical Synthesis of Câ€Ring Aryl Taxoids. Chemistry - A European Journal, 1997, 3, 399-409.	1.7	20

#	Article	IF	Citations
181	Fluorescent taxoids. Chemistry and Biology, 1996, 3, 1021-1031.	6.2	57
182	Taxoids: New Weapons against Cancer. Scientific American, 1996, 274, 94-98.	1.0	70
183	Die Eroberung von Taxol. Angewandte Chemie, 1995, 107, 2247-2259.	1.6	26
184	The Conquest of Taxol. Angewandte Chemie International Edition in English, 1995, 34, 2079-2090.	4.4	82
185	Enzymatic resolution of a key stereochemical intermediate for the synthesis of (â^')-taxol. Tetrahedron Letters, 1995, 36, 3291-3294.	0.7	29
186	Chemical Synthesis and Biological Evaluation of C-2 Taxoids. Journal of the American Chemical Society, 1995, 117, 2409-2420.	6.6	60
187	Total Synthesis of Taxol. 3. Formation of Taxol's ABC Ring Skeleton. Journal of the American Chemical Society, 1995, 117, 645-652.	6.6	162
188	Total Synthesis of taxol. 2. Construction of A and C ring intermediates and initial attempts to construct the ABC ring system. Journal of the American Chemical Society, 1995, 117, 634-644.	6.6	219
189	Total Synthesis of Taxol. 1. Retrosynthesis, Degradation, and Reconstitution. Journal of the American Chemical Society, 1995, 117, 624-633.	6.6	182
190	Chemistry and Biology of Taxol. Angewandte Chemie International Edition in English, 1994, 33, 15-44.	4.4	605
191	Synthesis of C-2 Taxol Analogues. Angewandte Chemie International Edition in English, 1994, 33, 1581-1583.	4.4	42
192	Conformation of a water-soluble derivative of taxol in water by 2D-NMR spectroscopy. Chemistry and Biology, 1994, 1, 107-112.	6.2	57
193	Total synthesis of taxol. Nature, 1994, 367, 630-634.	13.7	1,030
194	A Facile One-Pot Synthesis of Symmetrical and Unsymmetrical Acetaldehyde Acetals from Primary Alcohols. Synthetic Communications, 1992, 22, 687-692.	1.1	10
195	Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	0